Evidence for commissioning: connecting clinical outcomes to economic value
Commissioning decisions increasingly demand economic as well as clinical evidence. We outline how to make that connection rigorously.
Commissioners are routinely asked to allocate finite resources across competing priorities. Clinical evidence tells part of the story; economic evidence tells the rest. The difficulty lies in connecting the two in a form that supports an actual decision.
A budget impact analysis answers a different question from a cost-effectiveness analysis, and the two are frequently confused. The former addresses affordability within a fixed envelope; the latter addresses value relative to alternatives. Robust commissioning evidence usually requires both, clearly distinguished.
The credibility of health economic evidence depends heavily on the transparency of its assumptions. Where data is drawn from trials conducted in different populations, or where local pathways differ from those modelled, these limitations should be stated plainly. Evidence that acknowledges its boundaries is more useful, not less.
Done well, economic evaluation gives commissioners a defensible basis for difficult choices — one that connects clinical outcomes to economic value without overstating the certainty of either.
This insight reflects the analytical practice of AO Group and Services. It is provided for general information and does not constitute advice on any specific matter.